Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
09/15 PFIZER : Astellas Announce Positive Top-Line Results From Phase 3 Prosper Trial ..
09/15 ASTELLAS PHARMA : U.S. FDA Accepts for Review Astellas' Supplemental New Drug Ap..
09/14 ASTELLAS PHARMA : Announces Launch of 'Keep on Dancing' Sweepstakes
09/14 ASTELLAS PHARMA : Reports on Immunosuppressive Agents Findings from Astellas Pha..
09/13 ASTELLAS PHARMA : U.S. FDA Accepts for Review Astellas' Supplemental New Drug Ap..
09/11 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
09/08 ASTELLAS PHARMA : Announces Launch of 'Keep on Dancing' Sweepstakes
09/04 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
09/01 ASTELLAS PHARMA : Astella Announces Status of Acquisition of Own Shares (pdf 311..
08/31 ASTELLAS PHARMA : Researchers Submit Patent Application, "Pharmaceutical Composi..
More news
News from SeekingAlpha
09/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 15, 2017
09/14 Xtandi/ADT combo extends survival in late-stage prostate cancer study
09/13 FDA accepts Astellas' marketing application Myrbetriq/VESIcare combo for OAB
09/01 Astellas Changing Its Approach, But Investors Are Skeptical
08/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 24, 2017
Financials ( JPY)
Sales 2018 1 287 B
EBIT 2018 220 B
Net income 2018 188 B
Finance 2018 391 B
Yield 2018 2,46%
P/E ratio 2018 15,70
P/E ratio 2019 15,18
EV / Sales 2018 2,05x
EV / Sales 2019 1,99x
Capitalization 3 033 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 515  JPY
Spread / Average Target 3,3%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-10.15%27 205
JOHNSON & JOHNSON16.70%362 930
NOVARTIS11.20%225 262
ROCHE HOLDING LTD.4.56%220 102
PFIZER9.45%211 109
MERCK AND COMPANY12.38%179 869